Cargando…

Real-world experience using combination therapy with riociguat and risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial hypertension

Pulmonary arterial hypertension is a progressive disease that can lead to right-sided ventricular failure and premature death. Tailoring therapy to individual patient’s needs, along with regular risk assessment, is integral for optimal outcomes in patients with pulmonary arterial hypertension. Resul...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahay, Sandeep, Rahaghi, Franck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052464/
https://www.ncbi.nlm.nih.gov/pubmed/32166019
http://dx.doi.org/10.1177/2045894020910098
_version_ 1783502879441551360
author Sahay, Sandeep
Rahaghi, Franck
author_facet Sahay, Sandeep
Rahaghi, Franck
author_sort Sahay, Sandeep
collection PubMed
description Pulmonary arterial hypertension is a progressive disease that can lead to right-sided ventricular failure and premature death. Tailoring therapy to individual patient’s needs, along with regular risk assessment, is integral for optimal outcomes in patients with pulmonary arterial hypertension. Results from the AMBITION trial support the use of upfront combination of tadalafil and ambrisentan. In a recent analysis of risk assessment in pulmonary arterial hypertension, abridged versions of the REVEAL 2.0 risk score were shown to be comparable to the full tools. In this report, we present a case series of the use of riociguat in upfront combination or sequentially, and the impact on risk scores as determined by the abridged REVEAL Lite 2.0 approach.
format Online
Article
Text
id pubmed-7052464
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-70524642020-03-12 Real-world experience using combination therapy with riociguat and risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial hypertension Sahay, Sandeep Rahaghi, Franck Pulm Circ Case Series Pulmonary arterial hypertension is a progressive disease that can lead to right-sided ventricular failure and premature death. Tailoring therapy to individual patient’s needs, along with regular risk assessment, is integral for optimal outcomes in patients with pulmonary arterial hypertension. Results from the AMBITION trial support the use of upfront combination of tadalafil and ambrisentan. In a recent analysis of risk assessment in pulmonary arterial hypertension, abridged versions of the REVEAL 2.0 risk score were shown to be comparable to the full tools. In this report, we present a case series of the use of riociguat in upfront combination or sequentially, and the impact on risk scores as determined by the abridged REVEAL Lite 2.0 approach. SAGE Publications 2020-02-28 /pmc/articles/PMC7052464/ /pubmed/32166019 http://dx.doi.org/10.1177/2045894020910098 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Series
Sahay, Sandeep
Rahaghi, Franck
Real-world experience using combination therapy with riociguat and risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial hypertension
title Real-world experience using combination therapy with riociguat and risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial hypertension
title_full Real-world experience using combination therapy with riociguat and risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial hypertension
title_fullStr Real-world experience using combination therapy with riociguat and risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial hypertension
title_full_unstemmed Real-world experience using combination therapy with riociguat and risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial hypertension
title_short Real-world experience using combination therapy with riociguat and risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial hypertension
title_sort real-world experience using combination therapy with riociguat and risk assessment using reveal lite 2.0 in patients with pulmonary arterial hypertension
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052464/
https://www.ncbi.nlm.nih.gov/pubmed/32166019
http://dx.doi.org/10.1177/2045894020910098
work_keys_str_mv AT sahaysandeep realworldexperienceusingcombinationtherapywithriociguatandriskassessmentusingreveallite20inpatientswithpulmonaryarterialhypertension
AT rahaghifranck realworldexperienceusingcombinationtherapywithriociguatandriskassessmentusingreveallite20inpatientswithpulmonaryarterialhypertension